{"id":250853,"date":"2022-07-04T00:00:00","date_gmt":"2022-07-04T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/products\/research-reports\/report\/concid0004-2022-biopharma-hepatitis-c-virus-china-in-depth-hepatitis-c\/"},"modified":"2026-03-31T10:39:01","modified_gmt":"2026-03-31T10:39:01","slug":"concid0004-2022-biopharma-hepatitis-c-virus-china-in-depth-hepatitis-c-virus-china-in-depth-china-2022","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/concid0004-2022-biopharma-hepatitis-c-virus-china-in-depth-hepatitis-c-virus-china-in-depth-china-2022\/","title":{"rendered":"Hepatitis C Virus &#8211; China In-Depth &#8211; Hepatitis C Virus &#8211; China In-Depth (China) &#8211; 2022"},"content":{"rendered":"<p>China has the greatest burden of hepatitis C virus (<abbr title=\"hepatitis C virus\">HCV<\/abbr>) in the world. Chronically infected <abbr title=\"hepatitis C virus\">HCV<\/abbr> patients are at a high risk of developing cirrhosis, liver cancer, and early death if left untreated. Most <abbr title=\"hepatitis C virus\">HCV<\/abbr> patients in China are prescribed older generic agents such as interferon-\u03b1-2a, interferon-\u03b1-2b, pegylated interferon-\u03b1-2a (Peg-Intron), and sofosbuvir (Sovaldi). However, we expect that the recently launched coblopasvir (Beijing Kawin Biotechnology), ravidasvir (Ascletis Biotechnology\u2019s Asclevir), sofosbuvir \/ velpatasvir <abbr title=\"fixed-dose combination\">FDC<\/abbr> (Gilead Sciences\u2019\u00a0Epclusa) in addition to the emerging therapiesalfosbuvir (Daiichi Sankyo), seraprevir (CStone pharmaceuticals), and ropeginterferon alfa-2b (PharmaEssentia)\u2014set to launch for <abbr title=\"hepatitis C virus\">HCV<\/abbr> during the forecast period, will result in significant growth of the Chinese <abbr title=\"hepatitis C virus\">HCV<\/abbr> market over the 2021-2031 period. However, the need for additional effective therapies will remain high, representing a lucrative commercial opportunity for developers. Additionally, with the ongoing reforms in China\u2019s regulatory and access and reimbursement landscape, multinational companies are likely to be increasingly incentivized to enter the <abbr title=\"hepatitis C virus\">HCV<\/abbr> market.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>How large is China\u2019s drug-treatable <abbr title=\"hepatitis C virus\">HCV<\/abbr> population, and how will the drug-treatment rate change during the forecast period<\/li>\n<li>Which are the most commercially relevant drugs in China\u2019s <abbr title=\"hepatitis C virus\">HCV<\/abbr> market, and why? What are interviewed experts\u2019 insights into current treatment options? Which clinical needs remain unfulfilled?<\/li>\n<li>What are the key market access considerations for key therapies in the <abbr title=\"hepatitis C virus\">HCV<\/abbr> pipeline in China? What is their potential in terms of sales \/ uptake in <abbr title=\"hepatitis C virus\">HCV<\/abbr>? What are interviewed experts\u2019 opinions on the key emerging therapies?<\/li>\n<li>What are the key drivers and constraints in the Chinese <abbr title=\"hepatitis C virus\">HCV<\/abbr> market, and how will the market evolve over the forecast period?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p><em>China In-Depth<\/em> offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific A&#038;R environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.<\/p>\n<p><strong>Release date<\/strong><\/p>\n<p>July 2022<\/p>\n<p><strong>Geographies<\/strong><\/p>\n<p>China<\/p>\n<p><strong>Primary Research <\/strong><\/p>\n<p>Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and surveys with 50 infectious disease specialists.<\/p>\n<p><strong>Epidemiology <\/strong><\/p>\n<p>Diagnosed prevalence of <abbr title=\"hepatitis C virus\">HCV<\/abbr> in urban versus rural China. Clinically and market-relevant drug-treatable populations.<\/p>\n<p><strong>FORECAST<\/strong><\/p>\n<p>10-year, annualized, drug-level sales and patient share of key <abbr title=\"hepatitis C virus\">HCV<\/abbr> therapies through 2031, based on primary and secondary market research to formulate bottom-up assumptions.<\/p>\n<p><strong>E<\/strong><strong>MERGING<\/strong><strong> THERAPIES<\/strong><\/p>\n<p>PR \/ Phase III: 4 drugs. Phase II: 1 drug. Coverage of select early-phase products.<\/p>\n","protected":false},"template":"","class_list":["post-250853","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-hepatitis-c-virus","biopharma-product-china-in-depth","biopharma-geography-china","biopharma-geography-us","biopharma-date-960"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/250853","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":10,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/250853\/revisions"}],"predecessor-version":[{"id":576229,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/250853\/revisions\/576229"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=250853"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}